N/A N=57 Does Maternal Fever During Labor Analgesia Has Any Relationship With Maternal Ventilation?
Pregnancy
Primary: Changes in Maternal Ventilation During Labor Analgesia — 15.3; 12.6; 13.8 L/min
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=85 Carbidopa/Levodopa Combined With Behavioral Therapy for the Treatment of Cocaine Dependence
Cocaine Dependence
Primary: Confirmed Abstinence From Cocaine as Assessed by Treatment Effectiveness Score (TES) — 7; 9 cocaine-negative urines
Phase 4 N=24 Clinical Trial Comparing Endometrial Transformation With Subcutaneous Progesterone Versus Intramuscular Progesterone
Reproductive Techniques, Assisted
Primary: Predecidual Transformation — 1; 2; 7; 8 participants — p=0.3395
Phase 3 N=955 Immunogenicity and Safety Study of Proquad® and Infanrix® Hexa When Administered Concomitantly (V221-035)
Varicella · Measles · Mumps
Primary: Percentage of Participants Meeting Antibody Response Rate Criteria to Measles, Mumps, Rubella, and Varicella — 97.4; 96.3; 96.7; 98.6 Percentage of Participants
N/A N=60 Proton Pump Inhibitors and Dysbiosis in Cirrhosis
Cirrhosis · Healthy
Primary: Number of Patients With Overgrowth of Oral Microbiota in Their Stool After PPI Therapy Withdrawal or Initiation — 45; 15 Participants
Phase 3 N=46 Concomitant Longitudinal Evaluation of Adalimumab With Methotrexate in the Real World: the CLEAR Study
Psoriasis
Primary: Percentage of Participants Achieving a Satisfactory Response at Week 16 Based on Investigator Assessment — 33.3; 52.5; 50.0 percentage of participants
Phase 3 N=343 Study to Investigate Lacosamide as Add-on Therapy in Subjects ≥4 Years to <17 Years of Age With Partial Onset Seizures
Epilepsy
Primary: Change in Partial Onset Seizure (POS) Frequency Per 28 Days From Baseline to the Maintenance Period — -1.55; -3.05 Seizures per 28 days — p==0.0003
N/A N=111 Controlled Study of Kneehab XP for Patients Undergoing Total Knee Replacement
Total Knee Replacement
Primary: Isometric Strength Test — -21.9; -31.9 Newton-metres
Phase 2 N=82 Safety, Tolerability, and Efficacy Study of LFX453 in Actinic Keratosis Patients
Actinic Keratosis
Primary: Number of Adverse Events (AE)/Serious Adverse Events (SAE) as a Measure of Safety and Tolerability up to 20 Weeks — 10; 15; 9; 8 participants
Phase 4 N=1,034 Comparison of Terlipressin, Somatostatin, and Octreotide for Control of Variceal Bleeding
Variceal Bleeding, Cirrhosis
Primary: 5-day Treatment Failure (Failure to Control Bleeding, Rebleeding, or Death) — 218; 216; 225 participants
Phase 2 N=23 Vaccine Therapy in Patients With Stage II, III, or IV Epithelial Ovarian, Fallopian Tube, or Peritoneal Cancer
Fallopian Tube Cancer · Ovarian Cancer · Peritoneal Cavity Cancer
Primary: Percentage of Patients in Remission at 1 Year — 38.1; 38.8 percentage of participants
N/A N=59 Effects of Zoledronic Acid Versus Alendronate on Bone Loss After Kidney and Kidney/Pancreas Transplants
Renal Insufficiency
Primary: Percentage Change in Posterior Anterior (PA) Spine Bone Density From Baseline to 24 Months Post Transplant — 8.1; 6.6; 6.5 percentage of change of bone density
N/A N=112 Heart Rate Reducing Therapy in Cardiac CT Using Ivabradine and Bisoprolol
Bradycardia
Primary: Heart Rate — 65.1; 62.7 beats per minute
Phase 2 N=48 To Evaluate Safety, Pharmacokinetics and Pharmacodynamics of MEDI6012 in Subjects With Stable Coronary Artery Disease
Coronary Artery Disease
Primary: Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Treatment Emergent Serious Adverse Events (TESAEs) — 3; 2; 5; 2 Participants
Phase 2 N=30 Study Of GW823093 In Japanese Subjects With Type 2 Diabetes Mellitus
Diabetes Mellitus, Type 2
Primary: Standard Pharmacokinetic (PK) Parameter: Maximum Observed Plasma Drug Concentration (Cmax) — 238.166; 419.937; 262.523; 534.888 Nanograms per milliliter (ng/mL)